Article
IQVIA Pharma Deals Review 2024
IQVIA Pharma Deals
Mar 20, 2025

The IQVIA Pharma Deals Review of 2024 provides an insightful overview of deal activity in 2024, as well as an outlook for 2025.


Key information provided includes the following:
  • Top M&A and partnership deals in 2024
  • Deal activity by therapeutic area and development phase
  • Deal value analysis of M&A, licensing and R&D deals
  • Deal activity rankings of the top pharmaceutical companies

Report key highlights:
  • Selective M&A Approach: Deal volume dropped 8% from 2023, reflecting heightened buyer selectivity amid regulatory scrutiny
  • Quality Over Quantity in Licensing: While licensing activity fell 18%, fee values remained stable as firms prioritized strategic fit over volume
  • Strategic R&D Refocusing: Collaborative R&D alliances hit a 5-year low as industry leaders narrow therapeutic focus to maximize ROI
  • Opportunity Identification: Despite overall decline, the report identifies which therapeutic areas and deal structures showed resilience

Download the IQVIA Pharma Deals Review to gain critical insights and strategic guidance for navigating the evolving pharmaceutical landscape and maximizing business opportunities.

Related solutions

Contact Us